512784-20-2

Upstream product

• 512783-95-8 3-[2-oxo-3-(2-oxo-4-phenyl-oxazolidin-3-yl)-4-styryl-azetidin-1-yl]-N-(3-trifluoromethyl-benzyl)-succinamic acid tert-butyl ester 
• 14371-10-9 (E)-3-phenylpropenal 
• 512783-88-9 L-aspartic acid β-tert-butyl ester α-[3-(trifluoromethyl)benzyl]amide 
• 512784-03-1 3-[2-oxo-3-(2-oxo-4-phenyl-oxazolidin-3-yl)-4-styryl-azetidin-1-yl]-N-(3-trifluoromethyl-benzyl)-succinamic acid 
• 50541-93-0 4-amino-1-benzylpiperidine 
• 99333-55-8 2-(4(S)-phenyloxazolidin-2-on-3-yl)acetyl chloride 
• 123882-32-6 2-[(4S)-2-oxo-4-phenyl-1,3-oxazolidin-3-yl]acetic acid 
• 2740-83-2 3-(TRIFLUOROMETHYL)BENZYLAMINE 
• 512783-76-5 N-[(benzyloxy)carbonyl]-L-aspartic acid β-tert-butyl ester α-[3-(trifluoromethyl)benzyl]amide 

Relevant academic research and scientific papers

BETA-LACTAM CANNABINOID RECEPTOR MODULATORS

Described herein are substituted 2-(azetidin-2-on-l-yl)alkanoic acids, alkanedioic acids and 2-hydroxyalkyl alkanoic acids, and 2-acyl alkanoic acids, and derivatives thereof, that are capable of modulating activity at the cannabinoid-1 (CBl) and/or canna

β -LACTAMYL VASOPRESSIN V2 ANTAGONISTS

β-lactamyl alkanoic acids and pharmaceutical compositions thereof are described. Methods for treating various diseases and disease states using one or more β-lactamyl alkanoic acids are also described. Substituted 2-(azetidin-2-on-l-yl)alkanedioic acids,

Azetidinones as vasopressin V1a antagonists

The azetidinone LY307174 (1) was identified as a screening lead for the vasopressin V1a receptor (IC50 45 nM at the human V1a receptor) based on molecular similarity to ketoconazole (2), a known antagonist of the luteinizing hormone releasing h

BETA-LACTAMYLALKANOIC ACIDS FOR TREATING PREMENSTRUAL DISORDERS

0-lactamyl alkanoic acids are described. Methods for treating various premenstrual disorders using or more β-lactamyl alkanoic acids are also described.